VBI Looking To Market More Potent, Less Expensive Hepatitis B Vaccine
Sci-B-Vac was shown more effective at fewer doses than Engerix-B in a Phase III study. VBI Vaccines sees its hepatitis B vaccine hitting potential markets by 2021.
You may also be interested in...
VBI Is Ready To Take On HBV Vaccine Market
VBI’s Sci-B-Vac CONSTANT data firmly establishes the hepatitis B vaccine’s advantages over GSK’s longstanding Engerix-B, but it faces a tougher challenge with Heplisav-B from Dynavax.
Apellis Comes Closer To Taking On Alexion In PNH
Besting Alexion’s Soliris in a head-to-head Phase III trial portends a place in the market for Apellis’ competitor in paroxysmal nocturnal hemoglobinuria. But challenges dog both companies.
Iterum Anxiously Awaiting Other Results After SURE 3 Failure
Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.